Compounds · Brain & nerves · Growth hormone stimulation and release
CJC-1295 (with and without DAC)
Modified GRF (1-29), Mod GRF 1-29, CJC-1295 without DAC, CJC-1295 DAC, tetrasubstituted GRF (1-29)
Long-acting synthetic analog of growth hormone-releasing hormone, shown in early studies to raise GH and IGF-1 levels. Not FDA-approved for any use, with no major 2020–2025 trials; banned by WADA and sold as a research chemical, though a 2024 FDA status review opened it to further compounding evaluation without approving it.
0.1–0.3 mg of each nightly (blend)
Research score 40/100. Reference only, not a prescription.
- Growth Hormone Release
- Muscle Growth
- Fat Loss
- Recovery Enhancement
- Sleep Improvement
- US status
- Research Chemical
- Approval
- Not FDA Approved; Prohibited by WADA. Re-evaluated by FDA in 2024 for potential compounding.
- Evidence
- No active or recent clinical trials. Early-phase studies were conducted prior to 2020 but did not lead to clinical approval.
- Research score
- 40 / 100
- Indication
- Research Only - No Medical Indication
- Origin
- Canada
- Source category
- Brain & Nervous System
- Status group
- Research chemical
Mechanism
Binds GHRH receptors on the pituitary to trigger GH release via cAMP signaling. The DAC version attaches to serum albumin, extending its half-life from about 30 minutes to 6–8 days for sustained GH/IGF-1 elevation; the non-DAC form (Mod GRF 1-29) acts more briefly.
Safety file
Long-term human safety is unknown. The FDA has flagged cardiac event risk, plus concerns tied to elevated GH/IGF-1, including insulin resistance.
- Injection site reactions
- Temporary numbness in extremities
- Water retention
- Headache
- Joint stiffness
- Increased insulin resistance
Reconstitution
| Vial | 2 mL water | 3 mL water |
|---|---|---|
| 10 mg | 5 mg/mL | 3.33 mg/mL |
The classic GH pairing of CJC-1295 (No DAC) and Ipamorelin in a 1:1 ratio. The 10 mg vial holds 5 mg of each. Doses below are stated per peptide (they always move together); the calculator works in total blend mg, so 0.2 mg of each peptide is 0.4 mg of total blend.
- Use bacteriostatic water as the diluent.
- Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
- Swirl gently to mix, then leave it to dissolve. Do not shake.
- Give it a few minutes. The finished solution should be clear and colourless.
Protocol
Route: Subcutaneous
Why these two together
- CJC-1295 (No DAC) tells the pituitary to make growth hormone, while Ipamorelin tells it to release it: two different signals on the same gland
- The No DAC version is used because its short half-life lines up with Ipamorelin, which keeps the natural pulsing pattern intact
- They are combined in one syringe and one shot
Standard protocol (subcutaneous)
- 0.1 mg of each peptide before bed is the standard starting dose, moving to 0.2 mg of each for most people
- On the 10 mg vial (5 mg of each) at a 2 mL fill, 0.1 mg of each is a 0.04 mL draw (4 units) and 0.2 mg of each is 0.08 mL (8 units)
- Dose once daily, 5 days on, 2 days off
Timing matters
- Inject before bed, at least 2 hours after your last meal
- Food (especially carbs and fat) blunts the GH pulse, and the body releases its own GH overnight, so a fasted bedtime shot lines up with natural timing
- A fasted morning or post-workout dose is the other common slot
Titration and ceiling
- Start at 0.1 mg of each and increase by about 0.05 mg every 1 to 2 weeks if you want, up to a common ceiling of 0.3 mg of each per day (0.12 mL / 12 units at the 2 mL fill)
- 0.1 mg is already a saturating dose for many, so more is not always better
Dosing detail
- 0.1 mg of each peptide is the standard start, 0.2 mg of each suits most people, 0.3 mg of each is a common ceiling.
- At the 2 mL fill: 0.1 mg of each is 0.04 mL (4 units), 0.2 mg is 0.08 mL (8 units), 0.3 mg is 0.12 mL (12 units).
- Inject once daily before bed, fasted (2 hours after eating), 5 days on and 2 off.
- Both peptides are short-acting and share one syringe, so the pairing keeps the natural pulsatile GH release.
Duration
- Run 8 to 12 weeks (extend to 16 if desired), 5 on / 2 off, then a break.
Notes
- The most common GH peptide pairing.
- One daily shot covers both peptides instead of running two separate vials.
- A brief flush after injecting is common and harmless. Inject subcutaneously and rotate sites.
Storage and handling
- Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
- Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
- Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
- If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.
NovaEvum vial
Worksheet
2 mL bacteriostatic water yields 2.5 mg/mL of each peptide. A 100 mcg-of-each pulse is 4 units; 200 mcg of each is 8 units.
- Catalog fill
- 5 mg + 5 mg
- Typical water
- 2 mL
- Route
- Subcutaneous
- Cycle
- 8–12 weeks.
| Step | Amount | Frequency | Notes |
|---|---|---|---|
| Standard pulse | 100 mcg each | 1–2× daily | 4 units from a 2 mL reconstitution |
| Higher pulse | 200 mcg each | 1–2× daily | 8 units |
- You cannot change the CJC:Ipamorelin ratio from this vial.
- Do not also run a separate Ipamorelin vial on the same days unless you intend to raise only the secretagogue.
- Bacteriostatic water: 20–25 °C. Do not refrigerate the diluent.
- Amounts on this sheet are reconstitution math for the vial, not a recommendation.